Details:
The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.
Lead Product(s): Psychedelic Compound
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: MiHKAL GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 14, 2021
Details:
Under this agreement, VistaGen and Nuformix initially will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection.
Lead Product(s): 4-Chlorokynurenine,Probenecid
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: VistaGen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 27, 2020
Details:
The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.
Lead Product(s): Psilocybine,LSD
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020